The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Eylea Gets Orphan Status for Neovascular Glaucoma
July 1, 2019
- MHLW Data Show Big Improvement in Single-Product, Single-Price Transaction Rates
July 1, 2019
- Feburic Label to Be Revised due to CV Risk, but No Patient Restrictions to Be Required “at Present”
June 28, 2019
- PMD Amendment Bill Put under Continued Diet Review
June 28, 2019
- Chuikyo Reps Give Kudos to Formulary Initiatives, but Wary on Creating Medical Fees
June 27, 2019
- Chuikyo Raises No Objection to Earlier Price Cuts for LLPs, Payers Want Stricter Rule
June 27, 2019
- MHLW to Conduct Drug Price Survey before October Tax Hike: Chuikyo
June 27, 2019
- No Established Definition Is in Place for Formulary: Govt
June 27, 2019
- Janssen’s HIV Drug Symtuza to Join NHI Price List on July 3
June 27, 2019
- AMED Beats Target with Out-Licensing of 162 Drug Candidates in FY2015-FY2018
June 27, 2019
- Set Lower Premiums for Super Pricey Cell, Gene Therapies: Drug Pricing Organization
June 26, 2019
- Drug Pricing Organization Pitches Earlier Price Cuts for LLPs If AGs Launched, PMP Tweaks and More
June 26, 2019
- AMED to Fund Biomarker Development for Anti-PD-1 Antibodies
June 25, 2019
- Japan Cabinet Adopts 2019 Honebuto Policy, No Big Change Made on Drug Pricing
June 24, 2019
- Govt Earmarks 3 Billion Yen for AMED's Organ-on-Chip Project
June 21, 2019
- ICH to Discuss Use of RWD in Post-Marketing Safety Measures: Amsterdam Meeting
June 20, 2019
- MOF Panel Paper Reiterates Copay Raise for “Small-Risk” Disease Treatments
June 20, 2019
- MHLW Orders Label Revisions for Metformin, Blanket Contraindication for Patients with Severe Kidney Impairment
June 19, 2019
- Japan Approves Roche/Chugai’s Tumor-Agnostic Rozlytrek, Alnylam’s RNAi Drug and More
June 19, 2019
- LDP Inscribes AI Utilization for Drug Development in Honebuto Paper
June 19, 2019
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…